Hubei Biocause Pharmaceutical Co., Ltd. operates in the Industrial organic chemicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
companies in this sector in China:
Meihua Holdings Group Company Limited
(2016
sales of 11.09 billion Chinese Renmimbi [US$1.69 billion]
of which 94%
was Biological Ferment),
Lonkey Industrial Co., Ltd., Guangzhou
(9.85 billion Chinese Renmimbi [US$1.50 billion]
of which 100%
was Daily chemical industry), and
Fufeng Group Limited
(11.80 billion Chinese Renmimbi [US$1.80 billion]
of which 54%
was MSG).
Sales Analysis.
Sales increased substantially in 2016:
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 16.99 billion Chinese Renmimbi (US$2.58 billion)
for the
year ending
December of 2016.
This
represents
an
increase of 3,040.7%
versus 2015, when the company's sales were 541.07 million Chinese Renmimbi.
Sales of Pharmaceutical Manufacturing saw an increase
of
61.8% in 2016, from
297.54 million Chinese Renmimbi to 481.33 million Chinese Renmimbi.